Page last updated: 2024-11-13
difenacoum
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
diphenacoum: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 54676884 |
| CHEBI ID | 80743 |
| SCHEMBL ID | 122475 |
| SCHEMBL ID | 122474 |
| MeSH ID | M0060268 |
Synonyms (47)
| Synonym |
|---|
| AC-12415 |
| hsdb 6609 |
| 3-(3-p-diphenyl-1,2,3,4-tetrahydronaphth-1-yl) -4-hydroxycoumarin |
| ratak |
| wba 8107 |
| difenakum [czech] |
| neosorexa |
| einecs 259-978-4 |
| difenacoum [bsi:iso] |
| diphenacoum |
| 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin |
| 2h-1-benzopyran-2-one, 3-(3-(1,1'-biphenyl)-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy- |
| difenacoum |
| neosorexa pp580 |
| 3-(3-(1,1'-biphenyl)-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy-2h-1-benzopyran-2-one |
| coumarin, 3-(3-(4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxy- |
| 56073-07-5 |
| pp, rat |
| bdbm85791 |
| AKOS015960905 |
| sba3k9u26b , |
| difenakum |
| unii-sba3k9u26b |
| SCHEMBL122475 |
| SCHEMBL122474 |
| 3-(3-biphenyl-4-yl-1,2,3,4-tetrahydro-1-naphthyl)-4- hydroxycoumarin |
| difenacoum [mi] |
| 3-(3-p-diphenyl-1,2,3,4-tetrahydronaphth-1-yl) -4- hydroxycoumarin |
| difenacoum [iso] |
| diphenacoum [hsdb] |
| 2h-1-benzopyran-2-one, 3-(3-(1,1'-biphenyl)-4-yl-1,2,3,4- tetrahydro-1-naphthalenyl)-4-hydroxy- |
| 3-(3-(1,1'-biphenyl)-4-yl-1,2,3,4-tetrahydro-1- naphthalenyl)-4-hydroxy-2h-1-benzopyran-2-one |
| coumarin, 3-(3-(4-biphenylyl)-1,2,3,4-tetrahydro-1- naphthyl)-4-hydroxy- |
| CHEBI:80743 |
| DTXSID2058128 |
| pp 580 |
| FVQITOLOYMWVFU-UHFFFAOYSA-N |
| 3-(3-[1,1'-biphenyl]-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy-2h-chromen-2-one # |
| 2h-1-benzopyran-2-one, 3-(3-[1,1'-biphenyl]-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy- |
| 3-(3-(4-biphenylyl)-1,2,3,4-tetrahydro-1-naphthyl)-4-hydroxycoumarin |
| neosorex |
| difenacoum, pestanal(r), analytical standard |
| difenacoum 100 microg/ml in methanol |
| difenacoum 10 microg/ml in methanol |
| 2h-1-benzopyran-2-one, 3-(3-[1,1'-biphenyl]-4-yl-1,2,3,4-tetrahydro-1-naphthalenyl)-4-hydroxy-; difenacoum; diphenacoum; neosorexa; ratak |
| Q424775 |
| 4-hydroxy-3-[3-(4-phenylphenyl)-1,2,3,4-tetrahydronaphthalen-1-yl]chromen-2-one |
Research Excerpts
Overview
Difenacoum is a long-acting superwarfarin-type anticoagulant. exerts its effect through inhibiting vitamin K 2,3-epoxide reductase.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Difenacoum is a long-acting superwarfarin-type anticoagulant that exerts its effect through inhibiting vitamin K 2,3-epoxide reductase. " | ( Superwarfarin poisoning and its management. Card, DJ; Deuchande, K; Francis, S; Harrington, DJ, 2014) | 1.85 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Six difenacoum treatments failed in 14--42 days of baiting." | ( Field trials of second-generation anticoagulants against difenacoum-resistant Norway rat populations. Greaves, JH; Quy, R; Shepherd, DS, 1982) | 0.99 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "The differences in chemical structure between DFM on the one hand and BFM, FLO and DFTL on the other could explain the differences in bioavailability between these two groups of molecules." | ( Mass spectrometry characterization of anticoagulant rodenticides and hydroxyl metabolites. Benoit, E; Berlioz-Barbier, A; Fourel, I, 2020) | 0.56 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (3)
| Class | Description |
|---|---|
| ring assembly | Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved. |
| benzenes | Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. |
| naphthalenes | Any benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (57)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 20 (35.09) | 18.7374 |
| 1990's | 8 (14.04) | 18.2507 |
| 2000's | 6 (10.53) | 29.6817 |
| 2010's | 18 (31.58) | 24.3611 |
| 2020's | 5 (8.77) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 33.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (33.43) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 13 (20.63%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 50 (79.37%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||